ClinicalTrials.gg
Enrolling by invitationNCT06029114Updated Jan 13, 2026

MR Elastography of Cognitive Impairment

An observational study in Alzheimer Disease, Mild Cognitive Impairment and Healthy, sponsored by Mayo Clinic. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
450
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Alzheimer Disease by Mayo Clinic — 8 open to participants now, 10 under way, none of them phase 3. Alzheimer Disease · Mayo Clinic.

Started
2023
with 1 other
Observational
4 of 21
2 open now
Registered
19th of 21
by date

Among the 21 studies in Alzheimer Disease by Mayo Clinic, this one is one of 2 that started in 2023, is one of 4 observational ones, and was the 19th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

8 of the 21 studies in Alzheimer Disease by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Alzheimer Disease by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to further investigate the potential of brain stiffness as a novel biomarker for Alzheimer's disease.

Read the detailed description

Due to shifting demographics, the prevalence of dementia continues to increase in the population. To mitigate the effects of dementia will require new treatments working jointly with new methods for earlier and more sensitive diagnosis of the diseases. Magnetic resonance elastography (MRE) is a noninvasive technique for measuring tissue stiffness. MRE is a three-step process beginning with the introduction of shear waves into the tissue of interest with an external vibration source. The shear waves are imaged with a phase-contrast MRI pulse sequence and the resulting wave images are mathematically inverted to calculate tissue stiffness.

Preliminary data indicate that global brain stiffness is highly reproducible and that Alzheimer's disease causes a decrease in brain stiffness when compared to age- and gender-matched cognitively normal controls. The purpose of the proposed work is to further investigate the potential of brain stiffness as a novel biomarker for Alzheimer's disease. A comparison between brain stiffness and existing Alzheimer's disease biomarkers will help determine the biological basis of the observed stiffness change and in time may improve the sensitivity of Alzheimer's disease diagnosis and grading.

03

Conditions studied

  • Alzheimer Disease
  • Mild Cognitive Impairment
  • Healthy
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects will be selected from Mayo Alzheimer's Disease Research Center.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In good general health
  • No Active neurological or psychiatric conditions, if a prior neurological or psychiatric condition was present they must have returned to normal
  • No cognitive complaints
  • Normal neurological examination
  • No psychoactive medications
  • They may have a chronic medical condition that does not affect cognition
  • Low Aβ load Pittsburgh compound-B (PiB) ratio \<1.5

Inclusion Criteria for Mild Cognitive Impairment Subjects:

  • In good general health
  • Memory complaint documented by the patient and collateral source
  • Normal general cognitive function as determined by measure of general intellectual function and screening including the Short Test of Mental Status
  • Normal activities of daily living as documented by history and Record of Independent Living
  • Not demented by DSM-III-R criteria
  • Do have an objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists
  • High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5

Inclusion Criteria for Alzheimer's Disease Subjects:

  • In good general health
  • Dementia not a result of other medical or psychiatric conditions
  • Diagnosis of dementia made according to DSM-III-R criteria
  • Do have objective memory impairment determined by the clinical judgement of the neuropsychologists and neurologists
  • High Aβ load Pittsburgh compound-B (PiB) ratio ≥1.5

Exclusion criteria

Exclusion Criteria:

  • Alzheimer's disease or mild cognitive impairment due to a known genetic mutation
  • Major depression
  • History of primary or intracranial neoplasm, significant head trauma, intra-cerebral hemorrhage, hemispheric stroke
  • Contradictions to MRI imaging including but not limited to cardiac pacemakers, intraocular or intracranial metal, or other MRI incompatible devices.
  • Pregnant women. Women of child bearing potential will be given a urine pregnancy test prior the MRI scan. Results will be shared with the participant. If the pregnancy test is positive, the participant will not be included within the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy Control Group

    Subjects will have a magnetic resonance elastography (MRE) performed.

    Diagnostic Test: Magnetic Resonance Elastography (MRE)

  • Alzheimer's Disease Group

    Subjects will have a magnetic resonance elastography (MRE) performed.

    Diagnostic Test: Magnetic Resonance Elastography (MRE)

  • Mild Cognitive Impairment Group

    Subjects will have a magnetic resonance elastography (MRE) performed.

    Diagnostic Test: Magnetic Resonance Elastography (MRE)

Interventions

  • Diagnostic testMagnetic Resonance Elastography (MRE)

    Imaging technique performed on a Compact 3T MRI scanner that measures the stiffness (mechanical properties) of tissues.

06

What researchers measure

Primary outcomes

  1. Shear Stiffness

    Brain stiffness measured by the magnetic resonance elastography (MRE) reported in Kilopascal (kPa)

    Time frame: Baseline

Secondary outcomes

  1. Joint mechanical-diffusion

    MRE-based measurement of white matter regions of the brain

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Nov 2027, 49 months after the start.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 49 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2023
First posted
Sep 8, 2023
StartActual
Oct 11, 2023
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06029114
Lead sponsor
Mayo Clinic
Responsible party
John Huston (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Sep 8, 2023
Start date
Oct 11, 2023
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

John Huston, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion